Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 17Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 5Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Chronic-Phase 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Recurrence 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Hematologic Neoplasms 2Hematologic Diseases 2Congenital Abnormalities 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Cyclosporine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Anemia, Refractory × Busulfan × Clear all
NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Mesoblast, Ltd.

Phase 2 Withdrawn
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡